Comparing trials of glycoprotein IIb/IIIa receptor antagonists

被引：0
作者：
Fox, KAA [1 ]
机构：
[1] Univ Edinburgh, Cardiovasc Res Unit, Royal Infirm Edinburgh, Edinburgh EH3 9YW, Midlothian, Scotland
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 1999年 / 1卷 / 0R期
关键词：
clinical trials; glycoprotein IIb/IIIa inhibitors; PURSUIT; PRISM-PLUS; eptifibatide; tirofiban;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Large, well-designed clinical trials are the basis for determining the effectiveness and safety of pharmacological agents. Clinical trials may appear similar while differing in important aspects. Differences in patient population, end-point definition and trial management make it difficult to draw cross-trial conclusions regarding relative safety and efficacy of different agents. Newly released antiplatelet drugs that antagonize the glycoprotein (GP) IIb/IIIa receptor have been examined in important clinical trials of patients with acute coronary syndromes. The PURSUIT trial of eptifibatide and the PRISM-PLUS trial of tirofiban are presented as examples of trials with important differences in design, and the potential impact of trial design on trial outcome is discussed. In addition, we compare and contrast the results of trials of GP IIb/IIIa inhibitors in percutaneous coronary interventions and address how differences in these trials may have affected their outcomes.
引用
收藏
页码：R10 / R17
页数：8
相关论文
共 50 条
[41]   Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Segment Elevation Acute Coronary SyndromesA Review and Guide to Patient Selection [J].
Brett D. Atwater ;
Matthew T. Roe ;
Kenneth W. Mahaffey .
Drugs, 2005, 65 :313-324
[42]   Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor [J].
Christen, J. -R. ;
Soubrier, C. ;
Martinez, E. ;
Roumieu, V. ;
Darmon, O. ;
Scandaliaris, S. ;
Picou, L. ;
Cuisset, T. ;
Grados, A. ;
Bernit, E. ;
Ebbo, M. ;
Harle, J. -R. ;
Schleinitz, N. .
REVUE DE MEDECINE INTERNE, 2017, 38 (11) :769-773
[43]   Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery [J].
Cheng, DKF ;
Jackevicius, CA ;
Seidelin, P ;
Feindel, C ;
Rouleau, JL .
CANADIAN JOURNAL OF CARDIOLOGY, 2004, 20 (02) :223-228
[44]   Coronary intervention and glycoprotein IIb/IIIa integrin blockade [J].
Madan, M ;
Tcheng, JE .
CORONARY ARTERY DISEASE, 1999, 10 (08) :553-560
[45]   Platelet glycoprotein IIb/IIIa antagonists in ischemic stroke patients without endovascular therapy: A meta-analysis [J].
Xu, Dongjun ;
Yang, Cheng ;
Cao, Wei ;
Zhang, Xinyu ;
Yang, Shucong ;
Shen, Xuning ;
Xu, Jun ;
Yu, Huijie .
PHARMACOTHERAPY, 2024, 44 (08) :675-691
[46]   Intracranial Hemorrhages Associated with Intravenous Platelet Glycoprotein IIB/IIIA Receptor Inhibitors in the United States [J].
Adnan I. Qureshi ;
M. S. Hussain ;
Abu Nasar ;
Jawad F. Kirmani ;
Afshin A. Divani ;
Shafiudin Ahmed ;
M. Fareed K. Suri .
Cardiovascular Drugs and Therapy, 2005, 19 :371-373
[47]   Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab [J].
Coto, H .
JOURNAL OF INVASIVE CARDIOLOGY, 2000, 12 (10) :528-531
[48]   Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States [J].
Qureshi, AI ;
Hussain, MS ;
Nasar, A ;
Kirmani, JF ;
Divani, AA ;
Ahmed, S ;
Suri, MF .
CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (05) :371-373
[49]   Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors [J].
De Carlo, Marco ;
Maselli, Daniele ;
Cortese, Bernardo ;
Ciabatti, Nicola ;
Gistri, Roberto ;
Levantino, Maurizio ;
Balbarini, Alberto ;
De Caterina, Raffaele ;
Petronio, Anna Sonia .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 123 (03) :229-233
[50]   Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI [J].
Xu, Qiang ;
Yin, Jian ;
Si, Liang-yi .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 162 (03) :210-219
12345